Pharmaceutical Industry in the
Canton of Zug

Janssen-Cilag AG

Since 1979 · 51–100 empl.

Janssen-Cilag AG develops and commercializes pharmaceutical medicines and therapies in areas such as oncology, immunology, neuroscience and cardiopulmonary medicine.

Cilag GmbH International

Since 1984 · 51–100 empl.

Cilag GmbH International is part of Johnson & Johnson Innovative Medicine and focuses on the development and provision of medicines and therapies. Its work covers oncology, immunology, neuroscience, and cardiopulmonary areas.

Pharmact Holding AG

Since 1988 · 1–10 empl.

The core activity of Pharmact AG is the development and application of innovative medical solutions, particularly in the areas of atherosclerosis, diabetes mellitus, and severe liver diseases. The company develops genetically optimized enzymes and point-of-care tests (POCT) for the diagnosis and treatment of diseases, such as familial hypercholesterolemia. The core activity also includes research and development of new therapies and prevention products, as well as the commercial marketing of these products.

Medicor AG

Since 1993 · 1–10 empl.

Medicor AG provides solutions for a wide range of medical specialties, including cardiology, gastroenterology, pneumology, radiology, urology and veterinary medicine. Its services also include delivery, storage, repair and support.

Lipoid AG

Since 1995 · 21–50 empl.

The core activity of Lipoid GmbH is the development, manufacture and distribution of pharmaceutical active ingredients, in particular phospholipids, as well as cosmetics and dietary supplements. The company offers a wide range of products, including parenteral, oral, topical, pulmonary and ocular applications, Active Pharmaceutical Ingredients (API), health and nutrition products, as well as cosmetics and skin care products.

Dermapharm AG

Since 1995 · 21–50 empl.

The core activity of Dermapharm AG is the manufacture, development and distribution of high-quality dermatological and anti-inflammatory drugs, particularly in the field of skin health and allergies.

Biogen Switzerland AG

Since 1996 · 51–100 empl.

The core activity of Biogen is the research, development and production of medicines, in particular large and small molecular therapeutics, as well as biosimilars, with a focus on the treatment of severe diseases such as neurology, neuropsychiatry, immunology and rare diseases.

Roche Diagnostics International AG

Since 1998 · 500+ empl.

Roche Diagnostics International AG develops and supplies diagnostic systems and tests for hospitals, laboratories and medical practices. The organization integrates research and development, production, marketing and service functions to create instruments, fully automated in‑vitro diagnostic systems and digital solutions.

Ursapharm Schweiz GmbH

Since 1998 · 1–10 empl.

The core activity of URSAPHARM is the development, manufacture and marketing of pharmaceutical products, in particular eye care products such as HYLO and EvoTears, as well as systems and manufacturing solutions for the pharmaceutical industry.

NEURIM PHARMACEUTICALS AG

Since 1999 · 1–10 empl.

The core activity of Neurim Pharmaceuticals is the discovery and development of innovative medications for the treatment of central nervous system (CNS) disorders, with the goal of improving the lives of patients with unmet medical needs.

GlobeMed Pharma Group AG

Since 1999 · 11–20 empl.

The core activity of Cannapharm AG is the production and distribution of cannabis extracts and other cannabis-based products for medical purposes. The company specializes in the manufacture of high-quality cannabis extracts, which are cultivated and produced in Switzerland, and offers these products to the specialist trade and pharmaceutical industry.

Catalent Pharma Solutions GmbH

Since 2000 · 101–500 empl.

Catalent Pharma Solutions GmbH is a global contract development and manufacturing organization (CDMO) providing development, manufacturing and supply services to pharmaceutical, biotech and consumer health companies. Services include oral dose and softgel technologies, biologics and specialty manufacturing, clinical supply and formulation and delivery technology support.

Cilag Holding AG

Since 2001 · 1–10 empl.

Cilag Holding AG is part of the Johnson & Johnson group and manufactures pharmaceutical and medical products and active ingredients. The Schaffhausen site serves as a strategic development, launch and production centre for dosage forms, APIs and medicines.

Bristol-Myers Squibb SA

Since 2002 · 21–50 empl.

Bristol-Myers Squibb SA is a global biopharmaceutical company that discovers, develops and delivers medicines for serious diseases. It conducts research and development, runs clinical trials and commercializes treatments in areas such as oncology, HIV and cardiovascular disease.

PHT Pharmaceutical AG

Since 2003 · 1–10 empl.

PHT Pharmaceutical AG is a contract research, development and manufacturing organization (CRDMO) and chemical supplier offering CRO and CDMO services, process development and cGMP manufacturing, strategic sourcing, logistics, and quality/regulatory support for pharmaceutical, agrochemical and specialty chemical customers.

Wockhardt Bio AG

Since 2005 · 11–20 empl.

The company's core activity is the development, manufacture and marketing of pharmaceuticals, biotechnology products, active pharmaceutical ingredients (APIs) and specialized hospital services. The company focuses on research and development of new medicines, particularly antibiotics, and offers a wide range of dosage forms, including tablets, capsules, injection solutions and vaccines. It is also active in contract manufacturing of APIs and the production of specialized medicines.

Gilead Sciences Switzerland Sàrl

Since 2006 · 51–100 empl.

The core activity of Gilead is the development and manufacture of pharmaceuticals, particularly for the treatment of severe and life-threatening diseases such as HIV, liver diseases and cancer.

AKROSWISS AG

Since 2006 · 1–10 empl.

The core activity of Akroswiss is the development and marketing of innovative nasal treatments for central nervous system (CNS) diseases, particularly for epileptic seizures and anxiety disorders (claustrophobia) during MRI examinations. The company focuses on developing minimally invasive, intranasal drug formulations with a unique 360° function for rapid and effective administration.

Rapid Pharma Development GmbH

Since 2007 · 1–10 empl.

The core activity of Rapid Pharma Development GmbH is the provision of services for the development of pharmaceutical projects, particularly in the areas of: project management, CMC (Chemistry, Manufacturing and Controls), GMP auditing, regulatory consulting, development of active pharmaceutical ingredients (API) and formulations, analytical activities, and outsourcing management of pharmaceutical development projects. The company supports its customers in the development of medicinal products, from the early phase to market authorization, and offers a wide range of services to accelerate and optimize the development of pharmaceutical projects.

HealthWatch Swiss AG

Since 2007 · 11–20 empl.

The core activity of HealthWatch Swiss is the development, licensing and marketing of pharmaceuticals, particularly through strategic partnerships and licenses, to provide patients with access to high-quality medications while simultaneously opening up new business areas to ensure sustainable growth.

Alexion Pharma GmbH

Since 2007 · 21–50 empl.

The core activity of Alexion is the development and provision of life-changing therapies for people with rare diseases. The company focuses on researching, developing and delivering medicines tailored to the needs of patients with rare diseases, and strives to improve the quality of life of these individuals.

Ferring AG

Since 2007 · 21–50 empl.

Ferring AG is a biopharmaceutical company that develops medicines and therapies for gastroenterology, urology and reproductive medicine.

Merck (Schweiz) AG

Since 2007 · 11–20 empl.

Merck (Schweiz) AG is a commercial entity of the Merck Group operating in the healthcare sector. The company markets healthcare products and provides commercial services to customers in the health care field.

Clinuvel AG

Since 2008 · 21–50 empl.

The core activity of CLINUVEL is the development, manufacture and marketing of pharmaceutical products, in particular the product SCENESSE, as well as the expansion of the business into the cosmetics sector and other services within an integrated business model.

Swiss Cardio Technologies AG

Since 2008 · 11–20 empl.

Swiss Cardio Technologies AG develops and licenses Cardioplexol®, a standardized ultra‑low‑volume cardioplegic solution for use in cardiovascular surgery. The company is the exclusive global license holder for Cardioplexol®, which has marketing approvals in 10 EU countries and Switzerland and is marketed through regional partners.

Olympic Therapeutics AG

Since 2008 · 1–10 empl.

Olympic Therapeutics AG develops bacteriophages for the treatment of MRSA and other bacterial infections, focusing on research and development of therapeutic phage candidates. The company’s activities include identification and development of phage candidates, intellectual property protection, and preparation for clinical development and commercialization.

ViiV Healthcare GmbH

Since 2009 · 11–20 empl.

The core activity of ViiV Healthcare is the development, manufacture and marketing of medicines for the treatment of HIV and AIDS. The company is exclusively focused on combating HIV and AIDS and strives to leave no person living with HIV behind.

Primex Pharmaceuticals AG

Since 2010 · 11–20 empl.

The core activity of Primex Pharmaceuticals is the development, manufacture and marketing of pharmaceuticals, particularly in the field of anesthesia and sedation, with a focus on innovative solutions for pediatric sedation.

Zaphyr Pharmaceuticals AG

Since 2011 · 11–20 empl.

Zaphyr Pharmaceuticals AG in-licenses, out-licenses and commercializes FDA and European pharmaceutical products and branded generics for chronic diseases in the Middle East and Africa (MEA) region. The company also provides consultancy services (regulatory, market access, marketing & sales, business development and supply-chain support) and pursues manufacturing partnerships to localize production and transfer technology, with a focus on oncology.

SwissCore Group AG

Since 2012 · 1–10 empl.

The core activity of SwissCore is the development and provision of digital health solutions and services for the treatment of chronic diseases in emerging markets. This includes the manufacture and distribution of medicines produced, transported, stored and audited according to Swiss quality standards (Swissmedic). In addition, the company offers innovative telehealth solutions and services to support patients with chronic diseases.

Strides Pharma International AG

Since 2012 · 11–20 empl.

The core activity of Fairmed Healthcare AG is the development, manufacture and distribution of generic and biosimilar medicines, in particular for infectious diseases, as well as the production of active ingredients and finished medicinal products. The company also offers solutions for pharmacies, including the development of its own pharmacy brands.

Guerbet Imaging Switzerland AG

Since 2013 · 1–10 empl.

Guerbet Imaging Switzerland AG is part of the Guerbet Group and provides solutions and services for medical imaging. Its activities focus on diagnostic and interventional imaging products, including contrast agents, injectors, accessories and consumables.

Stallergenes Greer International AG

Since 2013 · 11–20 empl.

The core activity of Stallergenes Greer is the development, manufacture and marketing of products for allergology and specifically for allergen immunotherapy (AIT). The company is a world leader in allergen and AIT products and has a significant global presence.

Bluestone Pharma GmbH

Since 2013 · 11–20 empl.

The core activity of Bluestone Pharma is the development, manufacture and marketing of medical probiotics, in particular oral probiotics, used to treat and prevent various health conditions. The company offers turnkey solutions and private label options to customers and focuses on delivering scientifically proven health benefits through unique probiotic strains in areas with unmet needs.

Almeda Pharmaceuticals AG

Since 2013 · 1–10 empl.

The core activity of Almeda Pharmaceuticals AG is the development, manufacture and marketing of pharmaceutical products, in particular specialized medicines, generics and dietary supplements. The company focuses on the areas of oncology, transplantation medicine, CNS diseases, antimicrobial therapies, rare diseases and nutrition supplements. Almeda Pharmaceuticals AG positions itself as a reliable partner for the distribution and marketing of medicines in the CIS region (Commonwealth of Independent States) and other selected geographical regions.

CRISPR Therapeutics AG

Since 2013 · 101–500 empl.

The core activity of CRISPR Therapeutics is the development of gene therapeutic medicines, particularly through the application of CRISPR-Cas9 technology, to cure diseases at the molecular level. The company focuses on developing medicines for various diseases such as sickle cell anemia, β-thalassemia, cancer, autoimmune disorders, and regenerative medicine.

PTC Therapeutics Switzerland GmbH

Since 2014 · 21–50 empl.

The company's core activity is the development, manufacture and marketing of medicines for rare diseases. The company focuses on the discovery, development and global marketing of clinically differentiated medicines for patients with rare diseases.

Devatis AG

Since 2014 · 11–20 empl.

The core activity of Devatis AG is the manufacture and distribution of high-quality pharmaceutical finished products and active ingredients, particularly generics, in various therapeutic areas such as hematology, oncology, ophthalmology and respiratory system.